Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) news covers a late-stage biotechnology company focused on Lymphocyte Activation Gene-3 (LAG-3)–related immunotherapies for cancer and autoimmune disease. The company regularly reports clinical, regulatory and corporate developments across its diversified LAG-3 portfolio, led by the MHC Class II agonist eftilagimod alfa (efti) and the LAG-3 agonist antibody IMP761.
On this page, readers can follow updates on Immutep’s major oncology programs, including the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, as well as Phase II and investigator-initiated studies in head and neck squamous cell carcinoma, soft tissue sarcoma and metastatic breast cancer. News items highlight trial milestones such as patient enrolment progress, primary endpoint readouts, translational biomarker data and presentations at international conferences like the European Society for Medical Oncology (ESMO), the World Conference on Lung Cancer and the San Antonio Breast Cancer Symposium.
For autoimmune disease, Immutep publishes updates on the Phase I program for IMP761, a first-in-class LAG-3 agonist antibody designed to silence dysregulated self-antigen-specific memory T cells. News coverage includes safety, pharmacodynamic findings and proof-of-concept data from the ongoing first-in-human study.
Investors can also track regulatory interactions, such as Fast Track designations, FDA feedback on late-stage development strategies and completion of Project Optimus requirements, alongside business developments like the strategic collaboration and exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected global markets. Corporate news, including R&D tax incentives from French and Australian government programs and quarterly activity reports, provides additional context on funding and operational progress.
Bookmark this page to monitor Immutep’s latest announcements, clinical data disclosures and SEC Form 6-K filings that shape the outlook for IMMP and its LAG-3–focused pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant advancements in its clinical development strategy for the quarter ending March 31, 2023. The company initiated the AIPAC-003 Phase II/III trial for eftilagimod alpha (efti) in HER2-negative and triple-negative metastatic breast cancer, with the first patient enrollment expected in Q2 2023. Positive final data from the TACTI-002 trial showed a 39% overall survival rate at 21 months for patients with second-line non-small cell lung cancer (NSCLC). The TACTI-003 trial reached 75% enrollment, and top-line results are anticipated in H2 2023. Furthermore, the INSIGHT-003 trial's expansion aims to evaluate a triple combination therapy in NSCLC. Immutep maintains a robust cash position of A$55.2 million, providing a runway until June 2024.